Advanced Bionics enters SCS market with Precision
This article was originally published in The Gray Sheet
Executive Summary
PMA approval of the rechargeable spinal cord stimulation (SCS) implant for chronic pain April 28 marks entry into a $350 mil. U.S. market, the firm says. The PMA was supported by a literature review with safety data from 880 patients and efficacy results from 116 patients. The firm will compete primarily with Advanced Neuromodulation Systems and Medtronic, which offer Genesis and Itrel SCS, respectively. Precision is the first such device to offer rechargeability and "real-time" programming, Advanced Bionics claims...
You may also be interested in...
Maxwellia Delivers Two UK Menstrual Health Rx-To-OTC Switches
UK switch specialist Maxwellia delivers two “me too” reclassifications in the area of women's health: Evana Heavy Period Relief and Ultravana Period Pain Relief.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.